The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This null result from a randomized trial pushes back against the prevailing evidence that BB-12 helps prevent colds and flu, but because the study used a blend of strains, it doesn't rule out that BB-12 alone might still work — the picture is now genuinely contested.
This meta-analysis found a modest but statistically significant reduction in HDL cholesterol with chia seed supplementation, but the overall evidence is moderate to low quality and the effect is very small.
This is the first solid signal that curcumin might meaningfully lower systolic blood pressure, but the effect was observed within a COPD-specific meta-analysis, so it needs direct replication in a general population before it's actionable.
This is the first meta-analysis on barberry and blood pressure, and the effect size is unusually large for a dietary supplement, but the wide confidence interval and lack of specified dose mean the finding needs replication before you should act on it.
This single randomized trial found a strikingly large reduction in death among critically ill septic patients given L-carnitine, but because only 60 people were studied and two out of three earlier trials saw no effect, this result is an intriguing signal, not a proven therapy.
This meta-analysis pushes back against the earlier 2-out-of-3 studies that suggested L-arginine helped pain, but because the underlying body of evidence is still low (only 3 studies), the picture is now genuinely contested rather than settled.
This systematic review contradicts the mostly positive direction of earlier smaller studies, making the overall picture contested — the pooled result is null, but confidence is moderate, so this doesn't settle the question.
This pooled analysis of six studies adds moderate-strength evidence that vitamin D may meaningfully improve insulin secretion and glycemic control in those already struggling with blood sugar — but it doesn't yet tell us who should take what dose, and the effect hasn't been tested in healthy people.
This is early, small-scale evidence that selenium might help manage one aspect of gestational diabetes, but because the total sample is only 230 people and other important markers didn't budge, it's far from a slam dunk.
This meta-analysis suggests probiotics can selectively lower TNF-α (a driver of inflammation) in athletes, but the overall evidence is still low-strength, so don't expect a universal immune overhaul.
This meta-analysis provides the strongest evidence so far that probiotics like Bifidobacterium infantis M-63 may reduce systemic inflammation in people with rheumatoid arthritis and multiple sclerosis, though the effect is moderate and longer studies are needed to confirm durability.
This is the first solid evidence that vitamin D's effect on diabetes prevention may depend on your DNA, but it's a single trial finding that needs replication before you should act on it.
This large meta-analysis strengthens the case that St. John's Wort is a credible option for depression, though it’s one of the first indexed studies on this specific comparison, so the evidence is still building.
This is a high-confidence finding from 2,278 people across 4 randomized trials, showing a big cholesterol drop, but the missing dose detail means you can't just grab any black cumin product off the shelf and expect the same result.
This is the strongest signal so far that rice bran, a cheap and widely available byproduct, might meaningfully lower cholesterol, but with only 5 studies and no specified dose, it's not yet a slam dunk.
This is the first solid RCT linking Lactobacillus reuteri to a large reduction in gum pain and bone loss, but the effect is specific to periodontitis patients and needs replication before you should act on it.
This is one of the first meta-analyses to pool data on nigella seed for metabolic health, and the blood sugar drop is large enough to be clinically noticeable, though the lack of a fixed dose and the focus on already-sick patients means healthy people shouldn't expect the same effect.
Bacillus coagulans MTCC 5856 and Unique IS2 were ranked as top performers for reducing abdominal pain in a large meta-analysis, but because the dose was not reported and only three small studies underlie the finding, the result should be treated as promising but not definitive.
This is the first meta-analysis to link L-carnitine with major pain relief in osteoarthritis, but because it's early evidence and the exact dose used wasn't reported, the finding needs replication before you should act on it.
This is the first systematic review on folate for nerve pain, so while the effect is large and statistically significant, the missing dose detail and early-stage evidence mean it's promising but not yet definitive.
This study offers strong but preliminary evidence that combining whey protein with multicomponent exercise may help older adults with sarcopenia stand up from a chair more easily, a key functional outcome.
This is one of the first randomized trials to show a large, sustained drop in fasting blood sugar from curcumin in this specific population, but it's a single study with 114 people, so we'd want to see it replicated before getting too excited.